Ginsenoside Rg3, a promising agent for NSCLC patients in the pandemic: a large-scale data mining and systemic biological analysis

INTRODUCTION: Non-small cell lung cancer (NSCLC) patients are particularly vulnerable to the Coronavirus Disease-2019 (COVID-19). Currently, no anti-NSCLC/COVID-19 treatment options are available. As ginsenoside Rg3 is beneficial to NSCLC patients and has been identified as an entry inhibitor of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Zhenjie, Chen, Qianying, Zhong, Xiaoying, Chen, Huiqi, Yu, Runjia, Tang, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553969/
https://www.ncbi.nlm.nih.gov/pubmed/36249948
http://dx.doi.org/10.1016/j.jgr.2022.09.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553969/
https://www.ncbi.nlm.nih.gov/pubmed/36249948
http://dx.doi.org/10.1016/j.jgr.2022.09.006

Ejemplares similares